Release Date: May 01, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Envista Holdings Corp (NVST, Financial) delivered core growth of 0.2% and adjusted EBITDA margin around 13%, both in line with expectations.
- The company reported adjusted EPS of $0.24, slightly ahead of expectations.
- Progress was made on the $250 million share repurchase program announced previously.
- Growth was observed across most of the portfolio, including Consumables and Nobel Biocare, with improvements in customer service and Spark margins.
- Envista Holdings Corp (NVST) maintained its 2025 guidance of 1% to 3% core growth, approximately 14% adjusted EBITDA margins, and adjusted EPS of $0.95 to $1.05.
Negative Points
- Currency exchange rates negatively impacted sales year over year by about 140 basis points.
- The Specialty Products and Technology segment saw a decline of about 1 point.
- Adjusted gross margin decreased by 260 basis points versus the prior year, primarily due to foreign exchange rates.
- Free cash flow was an outflow of $5 million in Q1, attributed to the timing of incentive compensation and working capital.
- The global dental market remains stable but faces geopolitical uncertainties and deteriorating US consumer confidence indices.
Q & A Highlights
Q: Can you elaborate on your current tariff exposure and the steps you're taking to mitigate the impact?
A: Paul Keel, President and CEO, explained that the main tariff exposure areas are US goods imported into China and Chinese goods imported into the US. To mitigate this, Envista is shifting some of its China supply from the US to Sweden and expects suppliers to manage tariff impacts themselves. Additionally, Envista is qualifying new suppliers to enhance supply chain resilience.
Q: What are the April trends in terms of volume and conversion to higher ASP procedures like implants and clear aligners?
A: Paul Keel noted that the macro market trends in April were similar to Q1, with no significant shifts in procedure types. April started well, and there were no major changes in consumer behavior towards higher ASP procedures.
Q: Can you provide more details on the gross and net impacts of tariffs on your business this year?
A: Paul Keel stated that the guidance includes current tariff activities, and they are confident in mitigating these impacts in the second half of the year. The expected outcome remains the same as initially guided, despite wider error bars due to macro uncertainties.
Q: What are your expectations for VBP (Volume-Based Procurement) in China this year, and how is it reflected in your guidance?
A: Paul Keel mentioned that the ortho VBP is progressing as expected, with procedure cost VBP underway and supply cost VBP to follow. The guidance anticipates a soft first half in Brackets and Wires in China, with benefits expected in the second half.
Q: How are you managing pricing power in a tariff environment, and what is your strategy for capturing price increases?
A: Paul Keel explained that pricing power varies by country, category, and customer type. Innovation-driven products can capture higher prices, while commodity products are more price-sensitive. The US market is currently more price-sensitive compared to other regions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
